Tag Archives: PCRX

What Made Northland Securities Upgrade Pacira Pharmaceuticals’ Stock?

In a report released today, Tim Chiang from Northland Securities upgraded Pacira Pharmaceuticals (PCRX – Research Report) to Buy, with a price target of $67.00. The company’s shares closed last Friday at $60.77, close to its 52-week high of $64.44.

Friday’s Highlights at Noon: Celldex (CLDX), Brainstorm Cell Therapeutics (BCLI), Inovio Pharmaceuticals (INO), Nu Skin (NUS), Pacira Pharmaceuticals (PCRX)

So far Friday, July 3, NASDAQ is down -2.97% and the S&P is down -2.01%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Celldex (CLDX – Research Report), Brainstorm Cell Therapeutics (BCLI –

A Director at Pacira Pharmaceuticals (NASDAQ: PCRX) is Selling Shares

Yesterday, a Director at Pacira Pharmaceuticals (PCRX – Research Report), Paul Hastings, sold shares of PCRX for $96.11K. Following Paul Hastings’ last PCRX Sell transaction on June 06, 2018, the stock climbed by 11.0%. In addition to Paul Hastings, 6

RBC Capital Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)

RBC Capital analyst Randall Stanicky maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) on May 11 and set a price target of $56.00. The company’s shares closed last Wednesday at $41.93. According to TipRanks.com, Stanicky is currently

Pacira Pharmaceuticals (PCRX) Receives a Buy from Leerink Partners

Leerink Partners analyst Ami Fadia maintained a Buy rating on Pacira Pharmaceuticals (PCRX – Research Report) today and set a price target of $45.00. The company’s shares closed last Thursday at $42.35. According to TipRanks.com, Fadia is a 2-star analyst

Pacira Pharmaceuticals (PCRX) Received its Third Buy in a Row

After Leerink Partners and Piper Sandler gave Pacira Pharmaceuticals (NASDAQ: PCRX) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst Balaji Prasad maintained a Buy rating on Pacira Pharmaceuticals yesterday and set a price